Skip to content
Evigrade
ModerateClass III antiarrhythmics (Vaughan Williams)×Testosterone 5α-reductase types 1 and 2 inhibitors

Updated · Methodology

Mechanism

The body eliminates dutasteride mainly as metabolites, formed by the liver enzymes CYP3A4 and CYP3A5 (dutasteride summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Amiodarone and its metabolite desethylamiodarone inhibit CYP3A4 and the transport protein P-glycoprotein (amiodarone SmPC, AEMPS). In its section on CYP3A4 and P-glycoprotein inhibitors, the dutasteride SmPC says that long-term use with strong CYP3A4 inhibitors may raise dutasteride levels (dutasteride SmPC, AEMPS). No study has tested this pair. With verapamil and diltiazem, moderate CYP3A4 inhibitors that also inhibit P-glycoprotein, dutasteride blood levels were on average 1.6–1.8 times higher (dutasteride SmPC, AEMPS). According to the US dutasteride label, this rise is not clinically significant (dutasteride label, US Food and Drug Administration, FDA). Higher dutasteride levels are unlikely to inhibit 5-alpha reductase any further, and dutasteride itself inhibits neither CYP3A4 nor P-glycoprotein (dutasteride SmPC, AEMPS).

Symptoms

The documents describe no symptoms specific to this pair. If dutasteride levels rise, expect its usual adverse effects: impotence, decreased libido, ejaculation disorders including reduced semen volume, and breast tenderness and enlargement (dutasteride summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The sexual adverse effects may persist after dutasteride is stopped (dutasteride SmPC, AEMPS). High doses caused no new safety problems: up to 40 mg a day for 7 days in volunteers and 5 mg a day for 6 months in patients, against the usual 0.5 mg dose (dutasteride SmPC, AEMPS).

Management

The combination can be used: the documents do not name this pair and set no mandatory dose change. Amiodarone inhibits CYP3A4 and P-glycoprotein (amiodarone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If dutasteride adverse effects appear, consider less frequent dutasteride dosing. The dutasteride SmPC gives this option for long-term use with strong CYP3A4 inhibitors (dutasteride SmPC, AEMPS). The US dutasteride label asks for caution only with long-term use of strong CYP3A4 inhibitors such as ritonavir, and recommends no dose adjustment with verapamil or diltiazem (dutasteride label, US Food and Drug Administration, FDA). Amiodarone is not on the lists of strong inhibitors in the dutasteride documents. With enzyme inhibition, dutasteride may need more than 6 months of combined use to reach a new steady state (dutasteride SmPC, AEMPS). Amiodarone interactions can persist for several months after amiodarone is stopped (amiodarone SmPC, AEMPS, and label, FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Amiodarone

Other interactions with Dutasteride